ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conj…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Health Care Roundup: Market Talk Gain insight on Moderna, Novo Nordisk and more in the latest Market Talks covering the Health Care sector. | ||
Sector Update: Healthcare Stocks Advance in Afternoon Trading Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S | ||
 Arbutus Biopharma shares jump after unveiling $230 million share buyback plan Arbutus Biopharma Corporation (NASDAQ:ABUS) shares climbed 10. 3% in premarket trading on Friday after the biotechnology company announced plans to repurchase up to $230 million of its common stock through a modified Dutch auction tender offer. | ||
 ABUS Stock Surges 10% Today — What’s Driving This Super Rally? Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash. | ||
 Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest. | ||
 Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with a massive, non-dilutive liquidity boost while removing a significant overhang for […] | ||
 Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new international cases that raise legal and operational questions for the company’s COVID-19 vaccine business. See our latest analysis for Pfizer. The legal headlines around Pfizer’s mRNA vaccine coincide with a mixed price pattern, with the stock showing a 1-day share price return of 0.77% and a 7-day share price return of 2.85%, but a... | ||
Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines. The new cases extend beyond the existing U.S. litigation into several international jurisdictions. The lawsuits seek monetary damages and potential injunctions on vaccine products, raising legal and operational risks for Pfizer. Pfizer, listed as NYSE:PFE, is facing an expanded legal challenge as Arbutus Biopharma and Genevant Sciences... | ||
 Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug. | ||
 ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said. | ||